Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

SL, Koolen; PO, Witteveen; RS, Jansen; MH, Langenberg; RH, Kronemeijer; A, Nol; I, Garcia-Ribas; S, Callies; KA, Benhadji; CA, Slapak; JH, Beijnen; EE, Voest; JH, Schellens

doi:10.1158/1078-0432.ccr-11-0353

Public

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.

Shared by NobleBlocks on Jul 13, 2011 • 12:00 AM UTC

Authors:

Koolen SL

Witteveen PO

Jansen RS

Abstract

<h4>Purpose</h4>LY2334737 is an orally available prodrug of gemcitabine. The objective of this study was to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of daily administration of LY2334737 with or without erlotinib.<h4>Experimental design</h4>Patients with advanced ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!